- Home
- PKE vs CDXS Comparison
PKE vs CDXS Comparison
Compare PKE & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKE
- CDXS
- Stock Information
- Founded
- PKE 1954
- CDXS 2002
- Country
- PKE United States
- CDXS United States
- Employees
- PKE N/A
- CDXS N/A
- Industry
- PKE Military/Government/Technical
- CDXS Major Chemicals
- Sector
- PKE Industrials
- CDXS Industrials
- Exchange
- PKE Nasdaq
- CDXS Nasdaq
- Market Cap
- PKE 297.8M
- CDXS 332.0M
- IPO Year
- PKE N/A
- CDXS 2010
- Fundamental
- Price
- PKE $14.69
- CDXS $5.00
- Analyst Decision
- PKE
- CDXS Buy
- Analyst Count
- PKE 0
- CDXS 2
- Target Price
- PKE N/A
- CDXS $11.00
- AVG Volume (30 Days)
- PKE 61.1K
- CDXS 782.6K
- Earning Date
- PKE 01-14-2025
- CDXS 02-26-2025
- Dividend Yield
- PKE 3.41%
- CDXS N/A
- EPS Growth
- PKE N/A
- CDXS N/A
- EPS
- PKE 0.36
- CDXS N/A
- Revenue
- PKE $61,420,000.00
- CDXS $64,446,000.00
- Revenue This Year
- PKE N/A
- CDXS N/A
- Revenue Next Year
- PKE N/A
- CDXS $2.02
- P/E Ratio
- PKE $40.72
- CDXS N/A
- Revenue Growth
- PKE 15.45
- CDXS N/A
- 52 Week Low
- PKE $11.96
- CDXS $2.53
- 52 Week High
- PKE $16.96
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- PKE 53.98
- CDXS 53.10
- Support Level
- PKE $13.25
- CDXS $4.24
- Resistance Level
- PKE $14.75
- CDXS $5.51
- Average True Range (ATR)
- PKE 0.48
- CDXS 0.33
- MACD
- PKE 0.02
- CDXS -0.03
- Stochastic Oscillator
- PKE 83.24
- CDXS 59.84
About PKE Park Aerospace Corp.
Park Aerospace Corp designs develop and manufactures engineered, advanced composite materials and composite structures and assemblies and low-volume tooling for the aerospace markets and prototype tooling for such structures and assemblies. Geographically, the company derives a majority of revenue from North America and also has a presence in a company operates its business in Asia and Europe. It offers advanced composite Prepregs for Aircraft Structures and Interiors, Sigma Strut and Alpha Strut.
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.